MDB Capital Holdings, LLC Class A common Q4 FY2024 earnings call

• Launched eXoZymes in November 2024 despite challenging IPO market conditions, with the team successfully executing despite tough environment. • Screened thousands of opportunities, with a rapidly growing pipeline of high-quality new opportunities. • Increased headcount by 12%, had ~1,800 shareholders and 456 MDB Direct accounts by year-end. • Launched MDB Direct on clearing platform, onboarded investors including IRA assets via partnership with STRATA Trust. • Engaged with RIAs, angel groups, and PE firms, seeing interest in public venture as an alternative to traditional venture. • Highlighted performance of portfolio companies: HeartBeam (potential groundbreaking ECG product), ClearSign (scaling in market including hydrogen), eXoZymes (unique synthetic biology approach), and ongoing development of assets licensed from Mayo Clinic. • Operational efforts to build clearing firm, hire and train licensed back-office team, and expand international presence with Managua office.

• Expect a steady flow of new companies due to market dynamics in venture and private equity, including companies with revenues or more developed stages. • Hoping to present 1-2 new Big Idea investment opportunities in the next quarter. • Focus on expanding investor community through partnerships with RIAs, angel groups, etc., to increase reach and curate value-added investors.

• Regulatory uncertainties, including potential changes in broker-dealer regulation and unknown FDA approval timelines. • Market volatility, especially affecting the valuation of eXoZymes. • Uncertainty in grant funding and regulatory environment for research-related assets like those licensed from Mayo Clinic.

Q: Does Lou Basenese still work for the organization?

A: Lou left MDB to focus on media presence but remains a friend and backer of the firm.

Q: Discuss deconsolidation of Invizyne's financials for MDB stockholders and eXoZymes' investors.

A: Deconsolidation makes financials clearer, showing a gain from eXoZymes' IPO valuation (~$40M on a $5.6M investment), with future treatment reviewed for impairment.

Q: Number of Big Idea companies expected in 2025 and IPO timelines.

A: Hoping for 3-4 new Big Ideas, with one in advanced discussions for September, others in development.

Q: Regulatory winds under Trump administration.

A: Regulatory environment is changing, potentially easier for new offerings, but FDA and grant funding remain uncertain.

Q: Plans for dividends.

A: Wait for value-creating events in eXoZymes with sufficient trading volume to avoid disrupting the market.

Q: Investment in cash and resources relative to value creation.

A: Modest cash kept for new opportunities, value-add through equity positions is significant, aiming to maintain leveraged operation.